Global Human Rabies Immunoglobulin Market research
Global Human Rabies Immunoglobulin Market research

Human Rabies Immunoglobulin Comprehensive Study by Side effects (Pain, Fever, Headache, Others), Rabies (Encephalitic, Paralytic), Immunoglobulin (IgG, IgM, IgA, IgD, IgE) Players and Region - Global Market Outlook to 2026

Human Rabies Immunoglobulin Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Jan 2022 Edition 218 Pages 78 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Human Rabies Immunoglobulin Market Overview:
Rabies immunoglobulin (RIG) is an anti-rabies medicinal drug made up of antibodies. It is used to stop rabies in humans who have been uncovered to the virus. It's administered after the wound has been dealt with with cleaning soap and water or povidone-iodine, and it is accompanied with the aid of a rabies vaccination course. It is injected into the wound website online as nicely as into a muscle. People who have already been vaccinated towards rabies do no longer require it. Pain at the injection site, fever, and headache are all frequent facet effects. Anaphylaxis and different extreme allergic responses are infrequent. There is no proof that the use of it at some stage in being pregnant reasons damage to the baby. It acts by way of stopping the rabies virus from coming into nerve tissue through adhering to it. Rabies immunoglobulin is no longer advantageous as soon as the virus has penetrated the central apprehensive system.

Growth Drivers
  • Increasing prevalence of chronic disease

Roadblocks
  • High cost of healthy human plasma protein

Opportunities
  • Growth in research and development and subsequent technological advancements

Challenges
  • High competition among established players


Competitive Landscape:
The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies.
Some of the key players profiled in the report are CSL Behring (United States), Grifols (Spain), Sanofi (France), Sichuan Yuanda Shuyang (China), CNBG (China), Kamada (Israel), Shuanglin Bio (China), Weiguang Bio (China), Shanghai RAAS (China) and Bharat Serum (India). Analyst at AMA Research see Chinese Players to retain maximum share of Global Human Rabies Immunoglobulin market by 2026. Considering Market by Side effects, the sub-segment i.e. Pain will boost the Human Rabies Immunoglobulin market. Considering Market by Rabies, the sub-segment i.e. Encephalitic will boost the Human Rabies Immunoglobulin market. Considering Market by Immunoglobulin , the sub-segment i.e. IgG will boost the Human Rabies Immunoglobulin market.

In 2020, a renewed partnership agreement with the World Health Organization (WHO), consolidating a 20-year collaboration to fight some of the most Neglected Tropical Diseases (NTDs) and supporting the WHO in its commitment to sustainably eliminate sleeping sickness before 2030. With this new 5-year commitment, Sanofi will provide a consistent financial support with USD 25 million (USD 5 million/year) dedicated to disease management, including screening of populations, disease awareness campaign, capacity building, as well as drug donation. This sustainable commitment is key to success to come to the end of NTDs.

What Can be Explored with the Human Rabies Immunoglobulin Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Human Rabies Immunoglobulin Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Human Rabies Immunoglobulin
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Human Rabies Immunoglobulin market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Human Rabies Immunoglobulin market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers, Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Human Rabies Immunoglobulin Market?
The Human Rabies Immunoglobulin market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Human Rabies Immunoglobulin Market?
Top performing companies in the Global Human Rabies Immunoglobulin market are CSL Behring (United States), Grifols (Spain), Sanofi (France), Sichuan Yuanda Shuyang (China), CNBG (China), Kamada (Israel), Shuanglin Bio (China), Weiguang Bio (China), Shanghai RAAS (China) and Bharat Serum (India), to name a few.

3. What trending factors would impact Human Rabies Immunoglobulin Market growth most?
"Growing new innovations technology" is seen as one of major influencing trends for Human Rabies Immunoglobulin Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Side effects
  • Pain
  • Fever
  • Headache
  • Others

By Rabies
  • Encephalitic
  • Paralytic

By Immunoglobulin
  • IgG
  • IgM
  • IgA
  • IgD
  • IgE

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of chronic disease
    • 3.3. Market Challenges
      • 3.3.1. High competition among established players
    • 3.4. Market Trends
      • 3.4.1. Growing new innovations technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Rabies Immunoglobulin, by Side effects, Rabies, Immunoglobulin and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Human Rabies Immunoglobulin (Value)
      • 5.2.1. Global Human Rabies Immunoglobulin by: Side effects (Value)
        • 5.2.1.1. Pain
        • 5.2.1.2. Fever
        • 5.2.1.3. Headache
        • 5.2.1.4. Others
      • 5.2.2. Global Human Rabies Immunoglobulin by: Rabies (Value)
        • 5.2.2.1. Encephalitic
        • 5.2.2.2. Paralytic
      • 5.2.3. Global Human Rabies Immunoglobulin Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Human Rabies Immunoglobulin (Price)
  • 6. Human Rabies Immunoglobulin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL Behring (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Grifols (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sichuan Yuanda Shuyang (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CNBG (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kamada (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Shuanglin Bio (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Weiguang Bio (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shanghai RAAS (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bharat Serum (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Human Rabies Immunoglobulin Sale, by Side effects, Rabies, Immunoglobulin and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Human Rabies Immunoglobulin (Value)
      • 7.2.1. Global Human Rabies Immunoglobulin by: Side effects (Value)
        • 7.2.1.1. Pain
        • 7.2.1.2. Fever
        • 7.2.1.3. Headache
        • 7.2.1.4. Others
      • 7.2.2. Global Human Rabies Immunoglobulin by: Rabies (Value)
        • 7.2.2.1. Encephalitic
        • 7.2.2.2. Paralytic
      • 7.2.3. Global Human Rabies Immunoglobulin Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Human Rabies Immunoglobulin (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Rabies Immunoglobulin: by Side effects(USD Million)
  • Table 2. Human Rabies Immunoglobulin Pain , by Region USD Million (2015-2020)
  • Table 3. Human Rabies Immunoglobulin Fever , by Region USD Million (2015-2020)
  • Table 4. Human Rabies Immunoglobulin Headache , by Region USD Million (2015-2020)
  • Table 5. Human Rabies Immunoglobulin Others , by Region USD Million (2015-2020)
  • Table 6. Human Rabies Immunoglobulin: by Rabies(USD Million)
  • Table 7. Human Rabies Immunoglobulin Encephalitic , by Region USD Million (2015-2020)
  • Table 8. Human Rabies Immunoglobulin Paralytic , by Region USD Million (2015-2020)
  • Table 9. South America Human Rabies Immunoglobulin, by Country USD Million (2015-2020)
  • Table 10. South America Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 11. South America Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 12. South America Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 13. Brazil Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 14. Brazil Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 15. Brazil Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 16. Argentina Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 17. Argentina Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 18. Argentina Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 19. Rest of South America Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 20. Rest of South America Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 21. Rest of South America Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 22. Asia Pacific Human Rabies Immunoglobulin, by Country USD Million (2015-2020)
  • Table 23. Asia Pacific Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 24. Asia Pacific Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 25. Asia Pacific Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 26. China Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 27. China Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 28. China Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 29. Japan Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 30. Japan Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 31. Japan Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 32. India Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 33. India Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 34. India Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 35. South Korea Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 36. South Korea Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 37. South Korea Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 38. Taiwan Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 39. Taiwan Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 40. Taiwan Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 41. Australia Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 42. Australia Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 43. Australia Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 44. Rest of Asia-Pacific Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 45. Rest of Asia-Pacific Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 47. Europe Human Rabies Immunoglobulin, by Country USD Million (2015-2020)
  • Table 48. Europe Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 49. Europe Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 50. Europe Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 51. Germany Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 52. Germany Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 53. Germany Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 54. France Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 55. France Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 56. France Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 57. Italy Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 58. Italy Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 59. Italy Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 60. United Kingdom Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 61. United Kingdom Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 62. United Kingdom Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 63. Netherlands Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 64. Netherlands Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 65. Netherlands Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 66. Rest of Europe Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 67. Rest of Europe Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 68. Rest of Europe Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 69. MEA Human Rabies Immunoglobulin, by Country USD Million (2015-2020)
  • Table 70. MEA Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 71. MEA Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 72. MEA Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 73. Middle East Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 74. Middle East Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 75. Middle East Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 76. Africa Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 77. Africa Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 78. Africa Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 79. North America Human Rabies Immunoglobulin, by Country USD Million (2015-2020)
  • Table 80. North America Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 81. North America Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 82. North America Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 83. United States Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 84. United States Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 85. United States Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 86. Canada Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 87. Canada Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 88. Canada Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 89. Mexico Human Rabies Immunoglobulin, by Side effects USD Million (2015-2020)
  • Table 90. Mexico Human Rabies Immunoglobulin, by Rabies USD Million (2015-2020)
  • Table 91. Mexico Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2015-2020)
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Human Rabies Immunoglobulin: by Side effects(USD Million)
  • Table 103. Human Rabies Immunoglobulin Pain , by Region USD Million (2021-2026)
  • Table 104. Human Rabies Immunoglobulin Fever , by Region USD Million (2021-2026)
  • Table 105. Human Rabies Immunoglobulin Headache , by Region USD Million (2021-2026)
  • Table 106. Human Rabies Immunoglobulin Others , by Region USD Million (2021-2026)
  • Table 107. Human Rabies Immunoglobulin: by Rabies(USD Million)
  • Table 108. Human Rabies Immunoglobulin Encephalitic , by Region USD Million (2021-2026)
  • Table 109. Human Rabies Immunoglobulin Paralytic , by Region USD Million (2021-2026)
  • Table 110. South America Human Rabies Immunoglobulin, by Country USD Million (2021-2026)
  • Table 111. South America Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 112. South America Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 113. South America Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 114. Brazil Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 115. Brazil Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 116. Brazil Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 117. Argentina Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 118. Argentina Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 119. Argentina Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 120. Rest of South America Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 121. Rest of South America Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 122. Rest of South America Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 123. Asia Pacific Human Rabies Immunoglobulin, by Country USD Million (2021-2026)
  • Table 124. Asia Pacific Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 125. Asia Pacific Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 126. Asia Pacific Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 127. China Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 128. China Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 129. China Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 130. Japan Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 131. Japan Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 132. Japan Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 133. India Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 134. India Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 135. India Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 136. South Korea Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 137. South Korea Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 138. South Korea Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 139. Taiwan Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 140. Taiwan Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 141. Taiwan Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 142. Australia Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 143. Australia Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 144. Australia Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 145. Rest of Asia-Pacific Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 146. Rest of Asia-Pacific Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 147. Rest of Asia-Pacific Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 148. Europe Human Rabies Immunoglobulin, by Country USD Million (2021-2026)
  • Table 149. Europe Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 150. Europe Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 151. Europe Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 152. Germany Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 153. Germany Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 154. Germany Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 155. France Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 156. France Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 157. France Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 158. Italy Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 159. Italy Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 160. Italy Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 161. United Kingdom Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 162. United Kingdom Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 163. United Kingdom Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 164. Netherlands Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 165. Netherlands Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 166. Netherlands Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 167. Rest of Europe Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 168. Rest of Europe Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 169. Rest of Europe Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 170. MEA Human Rabies Immunoglobulin, by Country USD Million (2021-2026)
  • Table 171. MEA Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 172. MEA Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 173. MEA Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 174. Middle East Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 175. Middle East Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 176. Middle East Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 177. Africa Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 178. Africa Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 179. Africa Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 180. North America Human Rabies Immunoglobulin, by Country USD Million (2021-2026)
  • Table 181. North America Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 182. North America Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 183. North America Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 184. United States Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 185. United States Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 186. United States Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 187. Canada Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 188. Canada Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 189. Canada Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 190. Mexico Human Rabies Immunoglobulin, by Side effects USD Million (2021-2026)
  • Table 191. Mexico Human Rabies Immunoglobulin, by Rabies USD Million (2021-2026)
  • Table 192. Mexico Human Rabies Immunoglobulin, by Immunoglobulin USD Million (2021-2026)
  • Table 193. Research Programs/Design for This Report
  • Table 194. Key Data Information from Secondary Sources
  • Table 195. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Rabies Immunoglobulin: by Side effects USD Million (2015-2020)
  • Figure 5. Global Human Rabies Immunoglobulin: by Rabies USD Million (2015-2020)
  • Figure 6. South America Human Rabies Immunoglobulin Share (%), by Country
  • Figure 7. Asia Pacific Human Rabies Immunoglobulin Share (%), by Country
  • Figure 8. Europe Human Rabies Immunoglobulin Share (%), by Country
  • Figure 9. MEA Human Rabies Immunoglobulin Share (%), by Country
  • Figure 10. North America Human Rabies Immunoglobulin Share (%), by Country
  • Figure 11. Global Human Rabies Immunoglobulin share by Players 2020 (%)
  • Figure 12. Global Human Rabies Immunoglobulin share by Players (Top 3) 2020(%)
  • Figure 13. Global Human Rabies Immunoglobulin share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 16. CSL Behring (United States) Revenue: by Geography 2020
  • Figure 17. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 18. Grifols (Spain) Revenue: by Geography 2020
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2020
  • Figure 21. Sichuan Yuanda Shuyang (China) Revenue, Net Income and Gross profit
  • Figure 22. Sichuan Yuanda Shuyang (China) Revenue: by Geography 2020
  • Figure 23. CNBG (China) Revenue, Net Income and Gross profit
  • Figure 24. CNBG (China) Revenue: by Geography 2020
  • Figure 25. Kamada (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Kamada (Israel) Revenue: by Geography 2020
  • Figure 27. Shuanglin Bio (China) Revenue, Net Income and Gross profit
  • Figure 28. Shuanglin Bio (China) Revenue: by Geography 2020
  • Figure 29. Weiguang Bio (China) Revenue, Net Income and Gross profit
  • Figure 30. Weiguang Bio (China) Revenue: by Geography 2020
  • Figure 31. Shanghai RAAS (China) Revenue, Net Income and Gross profit
  • Figure 32. Shanghai RAAS (China) Revenue: by Geography 2020
  • Figure 33. Bharat Serum (India) Revenue, Net Income and Gross profit
  • Figure 34. Bharat Serum (India) Revenue: by Geography 2020
  • Figure 35. Global Human Rabies Immunoglobulin: by Side effects USD Million (2021-2026)
  • Figure 36. Global Human Rabies Immunoglobulin: by Rabies USD Million (2021-2026)
  • Figure 37. South America Human Rabies Immunoglobulin Share (%), by Country
  • Figure 38. Asia Pacific Human Rabies Immunoglobulin Share (%), by Country
  • Figure 39. Europe Human Rabies Immunoglobulin Share (%), by Country
  • Figure 40. MEA Human Rabies Immunoglobulin Share (%), by Country
  • Figure 41. North America Human Rabies Immunoglobulin Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • CSL Behring (United States)
  • Grifols (Spain)
  • Sanofi (France)
  • Sichuan Yuanda Shuyang (China)
  • CNBG (China)
  • Kamada (Israel)
  • Shuanglin Bio (China)
  • Weiguang Bio (China)
  • Shanghai RAAS (China)
  • Bharat Serum (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation